Fosfomycin — Membership Pricing

Other medications in Infections

• Ganciclovir
• Imipenem-Cilastatin
• Isoniazid
• Itraconazole
• Ketoconazole
• Lamivudine
• Ledipasvir
• Linezolid

About Fosfomycin

Fosfomycin is a unique antibiotic often prescribed for uncomplicated urinary tract infections (UTIs) due to its convenient single-dose regimen. It's a powerful tool against bacterial invaders, and understanding its role is key to effective treatment. At TheDrugClub, we believe in making essential medications like fosfomycin more accessible and affordable for our members, helping you manage your health without breaking the bank.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Fosfomycin is approved for (FDA label)

CONTEPO is an epoxide antibacterial indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including acute pyelonephritis caused by susceptible isolates of Escherichia coli and Klebsiella pneumoniae . ( 1.1 ) Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of CONTEPO and other antibacterial drugs, CONTEPO should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) 1.1 Complicated Urinary Tract Infections (cUTI), including Acute Pyelonephritis CONTEPO is indicated for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI), including acute pyelonephritis, caused by susceptible isolates of Escherichia coli and Klebsiella pneumoniae . 1.2 Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of CONTEPO and other antibacterial drugs, CONTEPO should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.

Source: Read the full FDA label on DailyMed. Label effective date: November 4, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Fosfomycin (FDA label)

CONTEPO for Injection contains 6 grams of fosfomycin, and is supplied as a white or almost white, sterile powder in single-dose vials, for constitution and further dilution. CONTEPO for Injection contains 6 grams of fosfomycin as a sterile powder in single-dose vials for reconstitution and further dilution. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 855574f2-39f8-43bc-a3d2-79dbb578cb94. SPL document ID: ab03fd88-8988-4165-ab2a-48a5da12c7ba. Label effective date: November 4, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Fosfomycin (FDA label)

The following adverse reactions are discussed in greater detail in the Warnings and Precautions section: Serum Electrolyte Abnormalities [see Warnings and Precautions ( 5.1 )] QT Prolongation [see Warnings and Precautions ( 5.2 )] Increased Transaminase Levels [see Warnings and Precautions ( 5.3 )] Hypersensitivity Reactions [see Warnings and Precautions ( 5.4 )] Neutropenia Including Agranulocytosis [see Warnings and Precautions ( 5.5 )] Clostridioides difficile -Associated Diarrhea [see Warnings and Precautions ( 5.6 )] Development of Drug-Resistant Bacteria [see Warnings and Precautions ( 5.7 )] Most common adverse reactions (incidence ≥2%) are transaminase elevations, hypokalemia, neutropenia, nausea, vomiting, diarrhea, hypocalcemia, hypernatremia, headache, and hypophosphatemia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Meitheal Pharmaceuticals Inc. at 1-844-824-8426 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 855574f2-39f8-43bc-a3d2-79dbb578cb94. SPL document ID: ab03fd88-8988-4165-ab2a-48a5da12c7ba. Label effective date: November 4, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Fosfomycin (FDA label)

CONTEPO is contraindicated in patients with known serious hypersensitivity to fosfomycin, or any of the excipients [ see Warnings and Precautions ( 5.2 ) ] . CONTEPO is contraindicated in patients with known serious hypersensitivity to fosfomycin, or any of the excipients. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 855574f2-39f8-43bc-a3d2-79dbb578cb94. SPL document ID: ab03fd88-8988-4165-ab2a-48a5da12c7ba. Label effective date: November 4, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Fosfomycin (FDA label)

Serum Electrolyte Abnormalities : CONTEPO contains 1980 mg sodium in each vial. The high sodium load associated with the use of CONTEPO may result in changes in serum electrolytes, such as increased levels of sodium and decreased levels of potassium, calcium and phosphorus. A low-sodium diet is recommended during CONTEPO treatment. Monitor serum electrolyte levels and fluid status during CONTEPO treatment. Monitor signs and symptoms of edema, particularly in patients with cardiac insufficiency, renal impairment, cirrhosis, hypertension, hyperaldosteronism, hypernatremia or pulmonary edema. ( 5.1 ) QT Prolongation: CONTEPO has been shown to prolong the QT interval in some patients in the clinical trial. Avoid CONTEPO in patients with known prolongation of the QT interval or ventricular arrhythmias, including a history of torsade de pointes. ( 5.2 , 7.1 ) Increased Transaminase Levels : Increase in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were reported in the clinical trial.

Source: FDA prescribing information (DailyMed). Set ID: 855574f2-39f8-43bc-a3d2-79dbb578cb94. SPL document ID: ab03fd88-8988-4165-ab2a-48a5da12c7ba. Label effective date: November 4, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Fosfomycin (FDA label)

Avoid co-administration of CONTEPO with drugs known to prolong the QT interval. ( 5.2 , 7.1 ) 7.1 Drugs that prolong QT interval Co-administration of CONTEPO with other drugs known to prolong the QT interval may increase the risk for ventricular arrhythmia. Avoid co-administration of CONTEPO with drugs known to prolong the QT interval, such as class IA or class III antiarrhythmic medications, tricyclic antidepressants, macrolides, and antipsychotics [see Warnings and Precautions ( 5.2 )] .

Source: FDA prescribing information (DailyMed). Set ID: 855574f2-39f8-43bc-a3d2-79dbb578cb94. SPL document ID: ab03fd88-8988-4165-ab2a-48a5da12c7ba. Label effective date: November 4, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.